Dyne Therapeutics (NASDAQ:DYN) executives outlined a slate of 2026 operational and regulatory milestones during a discussion ...

This week's podcast heads to Cincinnati, Atlanta, Detroit and more.

The Disability Podcast,” he talks about overcoming those challenges to achieve his dreams, pivoting when certain sports ...

Executives from Edgewise Therapeutics (NASDAQ:EWTX) highlighted recent clinical updates and upcoming milestones across the ...

Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026 Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key ...

New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene ...

The selected dose in the pivotal phase is lower than for other drug candidates in clinical trials or gene therapy drugs for Duchenne.

The Brookbush Institute continues to enhance education with new articles, new courses, a modern glossary, an AI Tutor, ...

Deramiocel has the potential to become the first therapy to address both skeletal and cardiac manifestations of Duchenne muscular dystrophyBLA supported by positive pivotal HOPE-3 Phase 3 results, ...

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today presented at the 2026 ...

La Follette High School DECA earned state awards in Lake Geneva, with multiple students qualifying for the international conference and leadership programs.

Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy ...